Perseo Pharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Investors
-
3
Perseo Pharma General Information
Description
Developer of an enzyme therapeutics platform designed to treat digestive diseases. The company's platform uses proprietary nanotechnology to offer oral enzyme therapies to protect the enzyme in a nano-shield and bind it specifically to the mucus of the small intestine, where the digestion takes place, enabling patients to eliminate the pill burden to be consumed.
Contact Information
Website
www.perseo-pharma.comCorporate Office
- Hofackerstrasse 40B
- 4132 Muttenz
- Switzerland
Corporate Office
- Hofackerstrasse 40B
- 4132 Muttenz
- Switzerland
Perseo Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 01-Aug-2025 | Completed | Generating Revenue | |||
| 2. Seed Round | 19-May-2020 | Completed | Generating Revenue | |||
| 1. Spin-Off | 14-Mar-2019 | Completed | Generating Revenue |
Perseo Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Perseo Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Perseo Pharma Patents
Perseo Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4763197-A1 | Functionalized atp-hydrolyzing enzyme compositions | Inactive | 19-Dec-2024 | ||
| WO-2026132355-A1 | Functionalized atp-hydrolyzing enzyme compositions | Pending | 19-Dec-2024 | ||
| EP-4763227-A1 | Functionalized branched-chain amino acid-degrading enzyme compositions | Inactive | 19-Dec-2024 | ||
| WO-2026132350-A1 | Functionalized branched-chain amino acid-degrading enzyme compositions | Pending | 19-Dec-2024 | ||
| EP-4763189-A1 | Nanoparticle compositions comprising pancreatic enzymes | Inactive | 19-Dec-2024 | A61K9/19 |
Perseo Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Perseo Pharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 7G Bioventures | Venture Capital | Minority | ||
| BioBac | Angel Group | Minority | ||
| Business Angels Switzerland | Angel Group | Minority |
Perseo Pharma FAQs
-
When was Perseo Pharma founded?
Perseo Pharma was founded in 2019.
-
Where is Perseo Pharma headquartered?
Perseo Pharma is headquartered in Muttenz, Switzerland.
-
What is the size of Perseo Pharma?
Perseo Pharma has 9 total employees.
-
What industry is Perseo Pharma in?
Perseo Pharma’s primary industry is Drug Discovery.
-
Is Perseo Pharma a private or public company?
Perseo Pharma is a Private company.
-
What is Perseo Pharma’s current revenue?
The current revenue for Perseo Pharma is .
-
How much funding has Perseo Pharma raised over time?
Perseo Pharma has raised $412K.
-
Who are Perseo Pharma’s investors?
7G Bioventures, BioBac, and Business Angels Switzerland have invested in Perseo Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
